| Overview |
| bs-4185R-PE |
| RelB Polyclonal Antibody, PE Conjugated |
| WB, FCM |
| Human, Mouse |
| Rat, Dog, Cow, Pig, Horse |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human RelB |
| 161-260/579 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5971 |
| Q01201 |
| Cytoplasm, Nucleus |
| I REL; IREL; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; RelB; Reticuloendotheliosis viral oncogene homolog B; Transcription factor RelB; v rel avian reticuloendotheliosis viral oncogene homolog; v rel reticuloendotheliosis viral oncogene homolog B; RELB_HUMAN; I-Rel. |
| The NFKB complex consists of NFKB1 or NFKB2 bound to REL, RELA, or RELB. The NFKB complex is inhibited by I kappa B proteins (NFKBIA, or NFKBIB), which inactivate NF kappa B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I kappa B proteins by kinases (IKBKA, or IKBKB,) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF kappa B complex. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz